DIR Return Create A Forum - Home
       ---------------------------------------------------------
       MS Speaks
  HTML https://msspeaks.createaforum.com
       ---------------------------------------------------------
       *****************************************************
   DIR MS Speaks
       *****************************************************
   DIR (Abst.) Recurrence of disease activity after ocrelizumab disco...
       1 replies
   DIR (Abst.) Cardiogenic shock after ocrelizumab infusion in RRMS (...
       1 replies
   DIR Severe late-onset neutropenia in a patient with MS treated wit...
       0 replies
   DIR (ECTRIMS) Ocrelizumab may double serious infection risk in MS
       0 replies
   DIR (ACTRIMS abst.) MS patients treated with ocrelizumab, aged 70 ...
       1 replies
   DIR Genentech updates Phase 3 Ocrevus high-dose study in people w/...
       0 replies
   DIR Ocrevus biosimilar (Xacrel) shows equivalent efficacy as MS tr...
       0 replies
   DIR (Nature) Ocrelizumab biosimilar Xacrel compared to Ocrevus...
       0 replies
   DIR (Abst.) The wearing-off phenomenon of ocrelizumab in patients ...
       1 replies
   DIR Subcutaneous Ocrevus Zunovo has FDA approval
       0 replies
       *****************************************************
   DIR Next Page